This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Floyd A. Davis, MD; Dusan Stefoski, MD
Multiple Sclerosis Center Rush-Presbyterian-St Luke's Medical Center 1725 W Harrison St Chicago, IL 60612

Arch Neurol. 1988;45(11):1180.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We read the special article "Steroid Therapy in Multiple Sclerosis" by Troiano et al¹ in the August 1987 issue of the ARCHIVES with interest. While we agree that high-dose corticosteroid therapy has a role in the treatment of acute exacerbations in multiple sclerosis (MS), it is unclear if this is superior to corticotropin therapy. Though not stating an unequivocal preference, the authors' point of view is more favorable to corticosteroid treatment. In their comparisons, they focus largely on the adrenal-stimulating action of corticotropin and assume the long-held notion that corticotropin treatment can be considered an indirect way of administering corticosteroids. However, recent studies indicate a more complex situation.

Corticotropin has been shown to directly regulate antibody responses² and also to potently suppress interferon gamma production in mouse spleen cell cultures.³ The latter effect is particularly noteworthy, in view of the recent demonstration that treatment . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?